Ana María Carrasco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana María Carrasco has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Colombo
Department of Basic and Clinical Oncology (DOBC), Faculty of Medicine, University of Chile, Santiago, Chile
1 shared publication - Brock Kingstad-Bakke
Department of Basic and Clinical Oncology, Faculty of Medicine, Universidad de Chile, Santiago 8330015, Chile
1 shared publication - Camilo Villaman
Centers of Research Excellence in Science and Technology, Science & Life, Santiago 8580702, Chile
1 shared publication - Carolina Bizama
Department of Pathology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
1 shared publication - Carolina Ibañez
Department of Hematology & Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 833150, Chile
1 shared publication - Erik Morales
Hospital Regional de Talca, Talca 3460000, Chile
1 shared publication
Latest Publications
- Open Access
- 8 September 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (9) , 899
Validation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries. To overcome some of these barriers, we have designed a 25-gene panel that contains predictive biomarkers for most current and near-future available therapies in Chile and Latin America. Library preparation was optimized to account for low DNA integrity observed in formalin-fixed paraffin-embedded tissue. The workflow includes an automated bioinformatic pipeline that accounts for the underrepresentation of Latin Americans in genome databases. The panel detected small insertions, deletions, and single nucleotide variants down to allelic frequencies of 0.05 with high sensitivity, specificity, and reproducibility. The workflow was validated in 272 clinical samples from several solid tumor types, including gallbladder (GBC). More than 50 biomarkers were detected in these samples, mainly in BRCA1/2, KRAS, and PIK3CA genes. In GBC, biomarkers for PARP, EGFR, PIK3CA, mTOR, and Hedgehog signaling inhibitors were found. Thus, this small NGS panel is an accurate and sensitive method that may constitute a more cost-efficient alternative to multiple non-NGS assays and costly, large NGS panels. This kind of streamlined assay with automated bioinformatics analysis may facilitate the implementation of precision medicine in Latin America.
- 8 September 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (9) , 899
Open AccessValidation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries. To overcome some of these barriers, we have designed a 25-gene panel that contains predictive biomarkers for most current and near-future available therapies in Chile and Latin America. Library preparation was optimized to account for low DNA integrity observed in formalin-fixed paraffin-embedded tissue. The workflow includes an automated bioinformatic pipeline that accounts for the underrepresentation of Latin Americans in genome databases. The panel detected small insertions, deletions, and single nucleotide variants down to allelic frequencies of 0.05 with high sensitivity, specificity, and reproducibility. The workflow was validated in 272 clinical samples from several solid tumor types, including gallbladder (GBC). More than 50 biomarkers were detected in these samples, mainly in BRCA1/2, KRAS, and PIK3CA genes. In GBC, biomarkers for PARP, EGFR, PIK3CA, mTOR, and Hedgehog signaling inhibitors were found. Thus, this small NGS panel is an accurate and sensitive method that may constitute a more cost-efficient alternative to multiple non-NGS assays and costly, large NGS panels. This kind of streamlined assay with automated bioinformatics analysis may facilitate the implementation of precision medicine in Latin America.